Neodyne Biosciences Announces That Early Clinical Experience With Embrace® Advanced Scar Therapy Will be Presented at the 2013 Annual Meeting of the American Society of Plastic Surgery in San Diego, CA

Published: Oct 16, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

MENLO PARK, Calif., Oct. 15, 2013 /PRNewswire/ -- Neodyne Biosciences, Inc., announced today that Geoffrey Gurtner, MD, FACS, of Stanford University and Ali Mosharrafa, MD, of Phoenix, AZ will present their clinical experience with the embrace® Advanced Scar Therapy device at the Annual Meeting of the American Society of Plastic Surgery (ASPS). embrace® Advanced Scar Therapy is rated highly by physicians and patients and stands alone as the only scar management technology proven effective with Level 1, peer-reviewed, randomized, controlled clinical study data.[1]

The key-opinion-leading Drs. Gurtner and Mosharrafa are distinguished as panelists discussing Healing Faster with Better Wounds during the ASPS Hot Topics in Plastic Surgery session on Friday, October 11, 2013 at the San Diego Convention Center. Dr. Gurtner will present his groundbreaking work in surgical scar minimization for the first time at ASPS this year. His presentation, In Pursuit of Scarless Wound Healing, reviews clinical studies on Neodyne Biosciences' dynamic, elastomeric stress-shielding device: embrace® Advanced Scar Therapy.

Bill Beasley, President and COO of Neodyne, hails Dr. Gurtner for his scientific work: "Neodyne has proven in Level 1 clinical studies that the mechanism of off-loading tension across a newly formed scar can dramatically and significantly affect post-surgical scarring. These studies not only show an improvement in scar appearance versus control, but they also conclude that this significant efficacy is delivered by a method consistently rated highly by physicians and patients."

Dr. Ali Mosharrafa's presentation, Management of Closed Hyper-proliferative Scars, focuses on his current clinical experiences using embrace® Advanced Scar Therapy. Dr. Michael Longaker, a founder and Chair of the Board of Directors of Neodyne Biosciences, commended Dr. Mosharrafa: "Neodyne and embrace® Advanced Scar Therapy have very strong evidence beginning with animal studies and progressing through two randomized controlled trials showing a highly significant reduction in scarring. It is very exciting to see the great results that plastic surgeons are getting with this product."

embrace® Advanced Scar Therapy is a new scar management technology indicated for the use in management of closed hyper-proliferative (hypertrophic and keloid) scars and has been in shown, in clinical studies, to significantly approve the appearance of scars. The technology was developed at Stanford University in response to demand from surgeons seeking improved outcomes in this field where patients judge surgeons by the appearance of their scars following surgery. embrace® Advanced Scar Therapy is the only scar management technology with Level 1 clinical data showing significant improvement in scar appearance. Neodyne Biosciences announced its first commercial sale of its product in February of this year.

Hot Topics Sessions at ASPS provide leading plastic surgeons the opportunity to discuss cutting-edge technology, techniques and research on new devices in plastic surgery. This year's session is chaired by Kenneth Rothaus, MD from New York City.

About Neodyne Biosciences, Inc.

Neodyne Biosciences ( is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.

Investor Relations Contacts:
Bill Beasley

[1] Lim, et al. "The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Control Trial." Plastic and Reconstructive Surgery. (In press).

SOURCE Neodyne Biosciences, Inc.

Help employers find you! Check out all the jobs and post your resume.

Back to news